As more biologics aimed at larger patient populations come to market, the effectiveness and appropriateness of copayments comes into question. This classic cost-sharing tool - developed for an earlier era's less expensive products - may not work in the biotech era.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/03/2016 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/23424345